Thursday, 25 July 2024


Polyplus Launches Innovative Plasmid for AAV Vector Production, Strengthening Its Position in Biologic and Cell & Gene Therapy Solutions

27 March 2024 | News

Expanding AAV Vector Production Capabilities with Off-the-Shelf Plasmid Solutions

Image Source : Public Domain

Image Source : Public Domain

 

Polyplus (part of Sartorius, a distinguished upstream solutions provider for biologic and cell and gene therapy production and a part of the Sartorius group, has announced the introduction of pPLUS® AAV-RC2, a groundbreaking RepCap plasmid tailored for the production of adeno-associated virus vector 2 (AAV2). This launch is a significant addition to Polyplus’s portfolio, aligning with the company’s strategic direction to become a leading provider of critical raw materials for AAV production.

The pPLUS AAV-RC2 plasmid, now available off-the-shelf, is designed to streamline the manufacturing process for AAV vectors, offering a ready-to-use solution that enhances both efficiency and reliability in vector production. This initiative complements the recent introduction of pPLUS AAV-Helper in September 2023, and is part of a broader strategy to offer a comprehensive range of RepCap plasmids catering to various AAV serotypes throughout 2024.

Roel Gordjin, Chief Commercial Officer of Polyplus, highlighted the company’s vision and progress, stating, “In 2020, we made a commitment to evolve into a leading delivery supplier with capabilities across the expanding range of modalities in the market. Since then, our portfolio has steadily expanded for transfection reagents, and now we are making our ambition to become a key supplier of critical raw materials for AAV production clear.” Gordjin emphasized the company’s proactive approach in understanding and meeting client needs, positioning Polyplus as a go-to supplier for AAV manufacturers.

The manufacturing of pPLUS AAV-RC2 is conducted entirely in-house at the Xpress Biologics GMP compliant facility in Belgium, ensuring the highest standards of quality and supply chain security. This move is indicative of Polyplus’s commitment to supporting the cell and gene therapy sectors with high-quality, dependable solutions that accelerate the transition from research to commercial-scale production.

With this launch, Polyplus not only reinforces its standing in the biotechnology industry but also underscores its dedication to supporting the advancement of gene therapies and biologics, offering innovative solutions that meet the complex needs of AAV vector production.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account